Coya Therapeutics, Inc. SEC filings COYA
Coya Therapeutics, Inc. has 230 filings in SEC EDGAR's recent list, going back to Jan 5, 2021. Its latest annual report, Form ARS, was filed on May 13, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 14, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | May 13, 2026 | — |
| DEF 14A | Proxy statement | May 13, 2026 | Jun 25, 2026 |
| DEFA14A | Additional proxy material | May 16, 2025 | — |
| DEF 14A | Proxy statement | May 16, 2025 | Jun 26, 2025 |
| DEFA14A | Additional proxy material | Mar 29, 2024 | — |
| DEFA14A | Additional proxy material | Mar 28, 2024 | — |
| DEF 14A | Proxy statement | Mar 28, 2024 | May 8, 2024 |
| DEFA14A | Additional proxy material | May 19, 2023 | — |
| DEF 14A | Proxy statement | May 19, 2023 | Jun 28, 2023 |
Showing 9 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- COYA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Houston, TX
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1835022
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.